Et studie af tolerabilitet, sikkerhed og effektivitet af asciminib hos patienter med Philadelphia-kromosom-positiv kronisk myeloid leukæmi i kronisk fase i Tyskland (ASC2ADHERE)
En ikke-interventionsundersøgelse af tolerabiliteten, sikkerheden og effektiviteten af Asciminib hos nydiagnosticerede og tidligere behandlede patienter med Philadelphia-kromosom-positiv kronisk myeloid leukæmi i kronisk fase i Tyskland - ASC2ADHERE-studiet
The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).
Studieoversigt
Status
Status
Betingelser
Betingelser
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Novartis Pharmaceuticals
- Telefonnummer: +41613241111
- E-mail: novartis.email@novartis.com
Undersøgelse Kontakt Backup
- Navn: Novartis Pharmaceuticals
Studiesteder
-
-
-
Amberg, Tyskland, 92224
- Rekruttering
- Novartis Investigative Site
-
Bad Friedrichshall, Tyskland, 74177
- Rekruttering
- Novartis Investigative Site
-
Bad Liebenwerda, Tyskland, 04924
- Rekruttering
- Novartis Investigative Site
-
Bad Saarow, Tyskland, 15526
- Rekruttering
- Novartis Investigative Site
-
Berlin, Tyskland, 10437
- Rekruttering
- Novartis Investigative Site
-
Berlin, Tyskland, 10365
- Rekruttering
- Novartis Investigative Site
-
Berlin, Tyskland, 12552
- Rekruttering
- Novartis Investigative Site
-
Berlin, Tyskland, 10559
- Rekruttering
- Novartis Investigative Site
-
Berlin, Tyskland, 12487
- Rekruttering
- Novartis Investigative Site
-
Bremerhaven, Tyskland, 27568
- Rekruttering
- Novartis Investigative Site
-
Buchholz Nordheide, Tyskland, 21244
- Rekruttering
- Novartis Investigative Site
-
Cottbus, Tyskland, 03046
- Rekruttering
- Novartis Investigative Site
-
Deggendorf, Tyskland, 94469
- Rekruttering
- Novartis Investigative Site
-
Detmold, Tyskland, 32756
- Rekruttering
- Novartis Investigative Site
-
Dorfen, Tyskland, 84405
- Rekruttering
- Novartis Investigative Site
-
Dortmund, Tyskland, 44263
- Rekruttering
- Novartis Investigative Site
-
Dresden, Tyskland, 01307
- Rekruttering
- Novartis Investigative Site
-
Dresden, Tyskland, 01127
- Rekruttering
- Novartis Investigative Site
-
Düren, Tyskland, 52353
- Rekruttering
- Novartis Investigative Site
-
Erfurt, Tyskland, 99085
- Rekruttering
- Novartis Investigative Site
-
Erfurt, Tyskland, 99084
- Rekruttering
- Novartis Investigative Site
-
Eschweiler, Tyskland, 52249
- Rekruttering
- Novartis Investigative Site
-
Göttingen, Tyskland, 37073
- Rekruttering
- Novartis Investigative Site
-
Hanover, Tyskland, 30161
- Rekruttering
- Novartis Investigative Site
-
Hanover, Tyskland, 30625
- Rekruttering
- Novartis Investigative Site
-
Hildesheim, Tyskland, 31135
- Rekruttering
- Novartis Investigative Site
-
Kiel, Tyskland, 24105
- Rekruttering
- Novartis Investigative Site
-
Leipzig, Tyskland, 04103
- Rekruttering
- Novartis Investigative Site
-
Leverkusen, Tyskland, 51375
- Rekruttering
- Novartis Investigative Site
-
Mutlangen, Tyskland, 73557
- Rekruttering
- Novartis Investigative Site
-
Naunhof, Tyskland, 04683
- Rekruttering
- Novartis Investigative Site
-
Neuss, Tyskland, 41462
- Rekruttering
- Novartis Investigative Site
-
Offenburg, Tyskland, 77654
- Rekruttering
- Novartis Investigative Site
-
Oldenburg, Tyskland, 26121
- Rekruttering
- Novartis Investigative Site
-
Parchim, Tyskland, 19370
- Rekruttering
- Novartis Investigative Site
-
Potsdam, Tyskland, 14467
- Rekruttering
- Novartis Investigative Site
-
Potsdam, Tyskland, 14482
- Rekruttering
- Novartis Investigative Site
-
Schorndorf, Tyskland, 73614
- Rekruttering
- Novartis Investigative Site
-
Schwetzingen, Tyskland, 68723
- Rekruttering
- Novartis Investigative Site
-
Soest, Tyskland, 59494
- Rekruttering
- Novartis Investigative Site
-
Stade, Tyskland, 21680
- Rekruttering
- Novartis Investigative Site
-
Torgau, Tyskland, 04860
- Rekruttering
- Novartis Investigative Site
-
Ulm, Tyskland, 89081
- Rekruttering
- Novartis Investigative Site
-
Wetzlar, Tyskland, 35578
- Rekruttering
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Baden-Baden, Baden-Wurttemberg, Tyskland, 76532
- Rekruttering
- Novartis Investigative Site
-
Heidenheim, Baden-Wurttemberg, Tyskland, 89522
- Rekruttering
- Novartis Investigative Site
-
Schwäbisch Hall, Baden-Wurttemberg, Tyskland, 74523
- Rekruttering
- Novartis Investigative Site
-
Winnenden, Baden-Wurttemberg, Tyskland, 71364
- Rekruttering
- Novartis Investigative Site
-
-
Bavaria
-
Aschaffenburg, Bavaria, Tyskland, 63739
- Rekruttering
- Novartis Investigative Site
-
Augsburg, Bavaria, Tyskland, 86152
- Rekruttering
- Novartis Investigative Site
-
Donauwörth, Bavaria, Tyskland, 86609
- Rekruttering
- Novartis Investigative Site
-
Herrsching am Ammersee, Bavaria, Tyskland, 82211
- Rekruttering
- Novartis Investigative Site
-
Kempten (Allgäu), Bavaria, Tyskland, 87439
- Rekruttering
- Novartis Investigative Site
-
Landsberg am Lech, Bavaria, Tyskland, 86899
- Rekruttering
- Novartis Investigative Site
-
Munich, Bavaria, Tyskland, 81241
- Rekruttering
- Novartis Investigative Site
-
Munich, Bavaria, Tyskland, 81377
- Rekruttering
- Novartis Investigative Site
-
Regensburg, Bavaria, Tyskland, 93053
- Rekruttering
- Novartis Investigative Site
-
-
Free Hanseatic City of Bremen
-
Bremerhaven, Free Hanseatic City of Bremen, Tyskland, 27576
- Rekruttering
- Novartis Investigative Site
-
-
Hesse
-
Kassel, Hesse, Tyskland, 34125
- Rekruttering
- Novartis Investigative Site
-
Offenbach, Hesse, Tyskland, 63065
- Rekruttering
- Novartis Investigative Site
-
-
Lower Saxony
-
Goslar, Lower Saxony, Tyskland, 38642
- Rekruttering
- Novartis Investigative Site
-
Rotenburg (Wümme), Lower Saxony, Tyskland, 27356
- Rekruttering
- Novartis Investigative Site
-
Twistringen, Lower Saxony, Tyskland, 27239
- Rekruttering
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Tyskland, 50674
- Rekruttering
- Novartis Investigative Site
-
Cologne, North Rhine-Westphalia, Tyskland, 50677
- Rekruttering
- Novartis Investigative Site
-
Cologne, North Rhine-Westphalia, Tyskland, 51103
- Rekruttering
- Novartis Investigative Site
-
Solingen, North Rhine-Westphalia, Tyskland, 42653
- Rekruttering
- Novartis Investigative Site
-
Wesel, North Rhine-Westphalia, Tyskland, 46483
- Rekruttering
- Novartis Investigative Site
-
-
Saxony
-
Zittau, Saxony, Tyskland, 02763
- Rekruttering
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Halle, Saxony-Anhalt, Tyskland, 06110
- Rekruttering
- Novartis Investigative Site
-
Merseburg, Saxony-Anhalt, Tyskland, 06217
- Rekruttering
- Novartis Investigative Site
-
-
Schleswig-Holstein
-
Oldenburg in Holstein, Schleswig-Holstein, Tyskland, 23758
- Rekruttering
- Novartis Investigative Site
-
-
Thuringia
-
Altenburg, Thuringia, Tyskland, 04600
- Rekruttering
- Novartis Investigative Site
-
Saalfeld, Thuringia, Tyskland, 07318
- Rekruttering
- Novartis Investigative Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Adult Ph+ CML-CP patients, either newly diagnosed or previously treated with one ATP-competitive TKI, who initiate TKI treatment as recommended by the treating physician in a hematology center in Germany.
Beskrivelse
Inclusion criteria:
- Written informed consent must be obtained before participation in the study/prior to any study-related documentation.
- Adult patients (≥18 years of age) with a confirmed diagnosis of Ph+ CML-CP. The presence of the Philadelphia chromosome may alternatively be confirmed by molecular detection of a BCR::ABL1 fusion gene/transcript (e.g., by reverse transcription polymerase chain reaction (RT-PCR)), in accordance with the World Health Organization (WHO) 2022 classification.
- Patients who are either newly diagnosed or have received treatment with exactly one prior TKI. Prior TKI treatment is only permitted for patients in the Asciminib Cohort. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be newly diagnosed and must not have received any prior TKI treatment.
- Patients for whom the treating physician has made a clinical decision to initiate treatment with asciminib or another TKI (imatinib, dasatinib, bosutinib, nilotinib) as part of routine care. The clinical decision for treatment must have been made prior to enrollment. Treatment must not have started more than 14 days before study inclusion, and treatment may also begin after baseline assessment.
- Patients willing to participate in routine follow-up visits and complete patient-reported outcome questionnaires over the course of the study.
Exclusion criteria:
-
Patients with contraindications to their respective chronic myeloid leukemia (CML) treatment as per the applicable Summary of Product Characteristics (SmPC) and relevant national treatment guidelines (e.g. Onkopedia CML), as well as additional disease- or treatment-related characteristics associated with distinct clinical scenarios that differ from the intended study population, including situations with specific treatment requirements or limited comparability, in which reliable interpretation of study outcomes may not be feasible, including the following asciminib specific considerations:
-
In first- or second-line treatment: presence of BCR::ABL1 fusion transcripts lacking exon a2 (e.g. e13a3, e14a3, e1a3).
-
In second-line treatment:
- known BCR::ABL1 mutations associated with partial or complete resistance to asciminib (e.g. M244V, F359I/V/C).
- presence of the BCR::ABL1 T315I mutation, regardless of eligibility for treatment according to SmPC (e.g., specific indication and dosing regimens).
-
-
Patients receiving or planned to receive asciminib or other TKIs outside the approved label (off-label use), including use in unapproved dosing regimens or frequency not covered by the respective SmPC.
-
Patients currently participating in an interventional clinical trial.
-
Patients unable or unwilling to provide written informed consent.
-
Patients who are unable to reliably complete patient-reported outcome questionnaires due to cognitive or language limitations relevant to the study assessments.
-
Patients for whom long-term follow-up is not feasible due to expected relocation or other logistical constraints.
-
The restriction to a maximum of one prior ATP-competitive TKI applies exclusively to patients treated with asciminib. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be TKI-naïve and are included at the start of their first-line TKI therapy and are not eligible if they have received any prior TKI treatment.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
|---|
|
Asciminib Cohort
Adult patients with Ph+ CML-CP, either newly diagnosed or previously treated with one TKI, who are treated with asciminib. |
|
Imatinib Cohort
Adult patients newly diagnosed with Ph+ CML-CP treated with imatinib who have not received any prior TKI treatment. |
|
Second-generation TKI Cohort
Adult patients newly diagnosed with Ph+ CML-CP treated with dasatinib, bosutinib, or nilotinib who have not received any prior TKI treatment. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Patients With Major Molecular Response (MMR) at 12 Months
Tidsramme: Month 12
|
MMR is defined as a BCR::ABL1 level ≤ 0.1% according to the International Scale (IS). |
Month 12
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Procentdel af patienter efter årsag til TKI-behandlingsbeslutning dokumenteret af den behandlende læge
Tidsramme: Baseline
|
Baseline
|
|
|
Andel patienter med dosisreduktion efter årsag til dosisreduktion
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
|
3, 6, 9, 12, 15, 18, 21 og 24 måneder
|
|
|
Procentdel af patienter med behandlingsafbrydelse efter årsag til afbrydelsen
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
|
3, 6, 9, 12, 15, 18, 21 og 24 måneder
|
|
|
Procentdel af patienter, der afbrød behandlingen efter årsag til afbrydelse
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
|
3, 6, 9, 12, 15, 18, 21 og 24 måneder
|
|
|
Tid til behandlingsophør
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
|
3, 6, 9, 12, 15, 18, 21 og 24 måneder
|
|
|
Tid til behandlingsafbrydelse
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
|
3, 6, 9, 12, 15, 18, 21 og 24 måneder
|
|
|
Tid til dosisreduktion
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
|
3, 6, 9, 12, 15, 18, 21 og 24 måneder
|
|
|
Tid til behandlingsophør på grund af bivirkninger (TTDAE)
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
|
3, 6, 9, 12, 15, 18, 21 og 24 måneder
|
|
|
Percentage of Patients by Clinical Characteristic
Tidsramme: Baseline
|
Characteristics include, but are not limited to, detection of Philadelphia chromosome or BCR::ABL1 transcript, prior treatment, and Eastern Cooperative Oncology Group (ECOG) performance status. |
Baseline
|
|
Percentage of Patients With Early Molecular Response (EMR) at 3 Months
Tidsramme: Month 3
|
EMR is defined as BCR::ABL1 ≤10% IS. |
Month 3
|
|
Percentage of Patients With Molecular Response 2 (MR2)
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
MR2 is defined as BCR::ABL1 ≤1% IS. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Percentage of Patients With MMR
Tidsramme: 3, 6, 9, 15, 18, 21, and 24 months
|
MMR is defined as BCR::ABL1 ≤0.1% IS. |
3, 6, 9, 15, 18, 21, and 24 months
|
|
Percentage of Patients With Deep Molecular Response: MR4.0
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
Deep Molecular Response (MR4.0): ≤0.01% BCR::ABL1 IS and Reference gene copies >10,000 ABL1 or >24,000 GUSB. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Percentage of Patients With Deep Molecular Response: MR4.5
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
Deep Molecular Response (MR4.5): ≤0.0032% BCR::ABL1 IS and Reference gene copies >32,000 ABL1 or >77,000 GUSB. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Percentage of Patients With Deep Molecular Response: MR5
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
Deep Molecular Response (MR5): ≤0.001% BCR::ABL1 IS and Reference gene copies >100,000 ABL1 or >240,000 GUSB. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Medication Adherence Report Scale (MARS-5) Score
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The MARS-5 questionnaire is a validated self-report questionnaire developed to assess patient adherence to prescribed medication, focusing on both intentional and unintentional non-adherence. It consists of 5 items, each rated on a 5-point Likert Scale from 0 (always) to 5 (never). The total score ranges from 5 to 25, with higher scores indicating better adherence to treatment. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The EORTC QLQ-C30 contains 30 questions answered by the patient. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (fatigue, pain, and nausea and vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but 2 questions have 4-point scales ranging from "Not at all" to "Very much." The 2 questions concerning global health status/QOL have 7-point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for CML (EORTC QLQ-CML24) Score
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The EORTC QLQ-CML24 was designed to supplement the QLQ-C30 - the QLQ-CML24 is not a stand-alone instrument but is to be used in conjunction with the QLQ-C30. The EORTC QLQ-CML24 is composed of 4 multi-item scales and 2 single-item scales. The module consists of 24 items assessing symptom burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items are measured on 4 levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores are averaged and transformed to 0 to 100. A higher score in symptom burden, impact on worry/mood, impact on daily life, and body image problems domains indicates a worse outcome. A higher score in satisfaction with social life and satisfaction with care and information domains indicates a higher level of satisfaction. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Work Productivity and Activity Impairment - General Health (WPAI-GH) Score
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The WPAI-GH is a patient-reported 6 item questionnaire which addresses absenteeism, presenteeism, overall work productivity loss, and activity impairment for the 7 days prior to the assessment. Work productivity and activity impairment outcomes are presented as impairment percentages ranging from 0 to 100 with a higher percentage indicating greater impairment and less productivity. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Neoplasmer
- Kronisk sygdom
- Sygdomsegenskaber
- Neoplasmer efter histologisk type
- Hæmatologiske sygdomme
- Leukæmi, myeloid
- Knoglemarvssygdomme
- Leukæmi
- Myeloproliferative lidelser
- Patologiske tilstande, tegn og symptomer
- Hemiske og lymfatiske sygdomme
- Leukæmi, myelogen, kronisk, BCR-ABL positiv
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CABL001J1DE02
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .